Abstract: The present invention provides the compounds of the formula (II): ##STR1## and salts and esters thereof wherein R.sub.1 is a hydrogen atom or an alkyl group of 1-4 carbon atoms and R.sub.2 is a hydrogen atom or an alkyl group of 1-4 carbon atoms or is joined to R.sub.1 to form part of a 5-, 6- or 7 membered carbocyclic ring. These compounds are .beta.-lactamase inhibitors able to enhance the effectiveness of pencillins and cephalosporins. Their preparation and compositions containing them are described.

Abstract: A unit dose pharmaceutical composition suitable for oral administration which composition comprises a pharmaceutically acceptable carrier, a desiccant, amoxycillin trihydrate equivalent to 20 mg to 1500 mg of amoxycillin and potassium clavulanate equivalent to 20 mg to 500 mg of clavulanic acid, with the proviso that the weight ratio of amoxycillin to clavulanic acid is in the range 12:1 to 1:1; characterized in that the composition is in tablet form, wherein the desiccant is edible and incorporated within the tablets.

Abstract: A synergistic combination is produced which comprises a synergistically effective amount of clavulanic acid or a pharmaceutically acceptable salt thereof and an antibacterially effective amount of a compound of the formula (II): ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen, hydroxyl or acetoxyl, R.sup.2 is methyl and R.sup.3 is CO.R.sup.4 wherein R.sup.4 is phenyl, isobutyl, furyl, thienyl or NHCH.sub.3 or R.sup.2 is joined to R.sup.3 so that NR.sup.2 R.sup.3 is an imidazolin-2-on-1-yl.

Abstract: A pharmaceutical composition for injection which comprises an aqueous sterile solution of a penicillin or salt thereof and from 1 to 10% of benzyl alcohol, a two-pack container or two-part syringe wherein one pack or part contains a penicillin or salt thereof in the form of a dry powder and the second pack or part contains an aqueous solution of benzyl alcohol, such that mixing the contents of the two packs or parts produces an aqueous solution of the penicillin and from 1 to 10% of benzyl alcohol, and a two-pack container or two-part syringe wherein one pack or part contains a penicillin in a solid free acid form, and the second part contains an aqueous solution of benzyl alcohol and substantially one equivalent of a basic pharmaceutically acceptable salt, such that mixing the contents of the two packs or parts produces an aqueous solution of a salt of the penicillin and from 1 to 10% of benzyl alcohol.

Abstract: The present invention provides a process for the preparation of a compound of the formula (IV): ##STR1## or salt or ester thereof wherein R.sup.1 and R.sup.2 are independently hydrogen; an organic radical bonded via a carbon atom to the ring carbon atom; a free, etherified or esterified hydroxy or mercapto group; an amino or acylamino group; or together R.sup.1 and R.sup.2 represent a group .dbd.CR.sup.5 R.sup.6 wherein R.sup.5 and R.sup.6 are the same or different and each represent hydrogen or a hydrocarbon or heterocyclic group optionally substituted with a functional group; and R.sup.3 represents an organic radical; which process comprises reacting a compound of the formula (V): ##STR2## wherein R.sup.x is hydrogen or a blocking group and R.sup.4 is an organic radical; with a thiol or reactive derivative thereof. The compounds of the formula (IV) are useful as antibiotics and .beta.-lactamase inhibitors, as are the compounds of the formula (V).

Abstract: Compounds of the formula ##STR1## wherein X is S, SO or SO.sub.2 and R is an inert hydrocarbon of up to 20 carbon atoms which will not lead to rapid degradation of the above compound unsubstituted or substituted and A is a group such and CO.sub.2 A represents a carboxylic acid group or a salt or ester thereof, are useful for their antibacterial activity and for their .beta.-lactamase inhibitory activity.

Abstract: A pharmaceutical composition adapted for administration to a human by injection which composition comprises an aqueous solution containing sodium amoxycillin and tri-sodium phosphate, the weight ratio of sodium amoxycillin present to the tri-sodium phosphate present being from 8:1 to 50:1.

Abstract: A class of 6-alkylidene penem compounds of formula (II) have antibacterial and .beta.-lactamase inhibitory properties: ##STR1## where R.sup.1 and R.sup.2 represent hydrogen or optionally substituted hydrocarbon or heterocyclic, and R.sup.3 represents hydrogen or an organic group.

Abstract: Ampicillin phthalidyl ester naphthalene-2-sulphonate, its preparation, and its use in pharmaceutical compositions to treat infections.

Abstract: A compound of the formula (I): ##STR1## and pharmaceutically acceptable salts thereof wherein R.sub.1 is hydrogen or C.sub.1-6 alkyl or an acyl group of 1 to 8 carbon atoms; n is 2, 3 or 4; X is halogen; and the OR.sub.1 and HN(CH.sub.2).sub.n X moieties are trans; has anti-hypertensive activity and a low level of cardiac side-effects.

Abstract: The compounds of the formula (II): ##STR1## and their pharmaceutically acceptable salts wherein R.sub.1 is a hydrogen, fluorine or chlorine atom or a hydroxyl, hydroxymethyl, methyl, methoxyl, amino, formamido, acetamido, methylsulphonylamido, nitro, benzyloxy, methylsulphonylmethyl, ureido, trifluoromethyl or p-methoxybenzylamino group; R.sub.2 is a hydrogen, fluorine or chlorine atom or a hydroxyl group; R.sub.3 is a hydrogen or chlorine atom or a hydroxyl group; R.sub.4 is a carboxylic acid group or a salt, ester or amide thereof; R.sub.5 is a hydrogen, chlorine or fluorine atom or a methyl, methoxyl or hydroxyl group or a carboxylic acid group or a salt, ester or amide thereof; R.sub.6 is a hydrogen atom or a methyl, or propyl group; X is an oxygen atom or a bond; and Y is an alkylene group of up to 6 carbon atoms or a bond have been found to possess anti-obesity and/or antihyperglycaemic activity.

Abstract: The compounds of the formula: ##STR1## and pharmaceutically acceptable salts and in-vivo hydrolysable esters thereof wherein R.sup.1 is a hydrogen atom or a group selected from OH, OSO.sub.3 H or a pharmaceutically acceptable salt or C.sub.1-4 alkyl ester thereof, OR.sup.2, SR.sup.3, OCOR.sup.2, OCO.sub.2 R.sup.3 or OCONHR.sup.3, where R.sup.2 is a C.sub.1-6 alkyl group or an optionally substituted benzyl group and R.sup.3 is a C.sub.1-6 alkyl group or an optionally substituted benzyl or an optionally substituted phenyl group; and R.sup.22 is a hydrogen atom, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 alkynyl wherein the triple bond is not present on the carbon adjacent to the sulphur atom, aralkyl, C.sub.1-6 alkanoyl, aralkanoyl, aryloxyalkanoyl or arylcarbonyl, any of such R.sup.22 groups being optionally substituted; with the proviso that when R.sup.22 is 2-aminoethyl R.sup.1 must be SR.sup.3 or OSO.sub.3 H or a pharmaceutically acceptable salt of C.sub.

Abstract: Esters of an acid of formula: ##STR1## which is termed "monic acid" have activity against Gram-positive and Gram-negative organisms.

Abstract: Compounds of the formula (I) ##STR1## wherein; n is 1 to 5Y is --CH.sub.2 --CH.sub.2 or --CH.dbd.CH--;R.sub.1 is hydrogen or CO.sub.2 R.sub.1 represents an ester group in which the R.sub.1 moiety contains from 1-12 carbon atoms;R.sub.2 is hydrogen, C.sub.1-4 alkyl, or phenyl;R.sub.3 is hydroxy or protected hydroxy;R.sub.4 is hydrogen, C.sub.1-9 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-6 alkyl, phenyl, phenyl -C.sub.1-6 alkyl, naphthyl, naphthyl C.sub.1-6 alkyl, any of which phenyl moieties or naphthyl moieties may be substituted by one or more halogen trifluoromethyl, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkoxy, phenyl C.sub.1-6 alkoxy or nitro groups;R.sub.5 is hydrogen, C.sub.1-6 alkyl, C.sub.5-8 cycloalkyl, phenyl, phenyl-C.sub.1-6 alkyl or phenyl C.sub.3-6 cycloalkyl, any of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or nitro groups; orR.sub.2 and R.sub.

Abstract: Compounds of the formula (I): ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sub.1 is hydrogen or C.sub.1-6 alkyl, and R.sub.2 is hydroxy, C.sub.1-4 alkylsulphonyloxy or p-toluenesulphonyloxy are useful for the prophylaxis and treatment of diseases due to allergic response in mammals. Processes for their preparation are described.

Abstract: This invention provides a novel process for the preparation of clavulanic acid and pharmaceutically acceptable salts and esters thereof which process utilizes the preparation of the tertiary-butylamine salt of clavulanic acid optionally in the form of an acetone solvate and subsequently converting said salt into the desired product.

Abstract: Compounds A - B - C wherein A is 2 imidazolinyl or N-alkyl derivative thereof, B is oxygen, sulphur, CR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are hydrogen or alkyl, or NR.sup.3 wherein R.sup.3 is hydrogen or alkyl, and C is a 5 - or 6 - membered carbo- or heterocyclic group having a nitrogen containing substituent and up to two other substituents, are useful in treatment of diarrhoea or scours. Certain compounds A - B - C are novel.

Abstract: The present invention provides a process for the preparation of a fused bicyclic .beta.-lactam containing compound having an optionally salified free carboxylic acid group which process comprises the reaction of an ester of the formula (I): ##STR1## with halide ion; wherein R is the residue of the fused bicyclic .beta.-lactam containing compound, R.sup.1 is an alkyl group of 1-6 carbon atoms optionally substituted by an alkoxy group of 1-4 carbon atoms or is an optionally substituted phenyl group or an alkyl group of 1-4 carbon atoms substituted by an optionally substituted phenyl group; and R.sup.2 is a hydrogen atom or an alkyl group of 1-4 carbon atoms or is joined to R.sup.2 to form part of a 5- or 6- membered carbocyclic or heterocyclic ring.

Abstract: The compounds of the formula (II): ##STR1## wherein R.sub.1 is a group such that CO.sub.2 R.sub.1 is a carboxylic acid group or a salt or ester thereof; R.sub.2 is a group of the sub-formula (a) or (b):--CR.sub.4 .dbd.C(R.sub.5) NH.CO.sub.n R.sub.6 (a)--CR.sub.7 .dbd.C(R.sub.8)R.sub.9 (b)wherein R.sub.4 is a hydrogen atom or a lower alkyl group; R.sub.5 is a hydrogen atom or a lower alkyl group; R.sub.6 is a lower alkyl, phenyl, fluorophenyl, chlorophenyl, bromophenyl or benzyl group; and n is 1 or 2; R.sub.7 is a hydrogen or a lower alkyl group; R.sub.8 is a hydrogen atom or a lower alkyl group; R.sub.9 is a hydrogen atom or a lower alkyl or phenyl group; R.sub.3 is a group of the sub-formula (c):CR.sub.10 R.sub.11 R.sub.12 (c)wherein R.sub.10 is a hydrogen atom or a hydroxyl or O.CO.R.sub.13 or O.CO.OR.sub.13 group where R.sub.13 is a lower alkyl, phenyl, benzyl, fluorobenzyl, chlorobenzyl, bromobenzyl, lower alkoxybenzyl or nitrobenzyl group; R.sub.11 is a hydrogen atom or a lower alkyl group; R.sub.

Abstract: A compound of formula (I) or a salt thereof: ##STR1## wherein R.sup.1 is an amino group, an azido group, or an acylamino group as found in antibacterially active penicillins or cephalosporins;R.sup.2 is a hydrogen atom or a C.sub.1-4 alkyl group;R.sup.3 is a hydrogen atom, or a C.sub.1-4 alkyl group optionally substituted by a carboxyl, carboxylic ester, hydroxy, C.sub.1-4 alkyloxy, acyloxy or heterocyclylthio group; andR.sup.4 is hydrogen or a readily removable carboxyl protecting group.The compounds wherein R.sup.1 is an acylamino group are found in known antibacterially active penicillins and cephalosporins and wherein R.sup.4 is a hydrogen, a pharmaceutically acceptable salting ion or an in vivo hydrolyzable ester forming radical may be formulated in pharmaceutical compositions.Processes for the preparation of the compound (I) are also described.